EN DE
Watch Rainmed Medical Ltd for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Rainmed Medical Ltd (2297) fair value: what the stock is really worth

As of Nov 13, 2026: fair value (intrinsic value) of Rainmed Medical Ltd stock HK$0.13, price HK$0.14, that is 4.3% below the price, quality 33 out of 100. Rating: fairly valued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare HK · Based in China

RM Rainmed Medical Ltd logo Thin data Nov 10, 2026

Rainmed Medical Ltd

2297 · HK

The stock is already about fairly priced, weak company and falling price: meets none of the 3 rules.

Get notified free when this changes
Low debt 
Revenue last quarter +41% vs. a year ago. 
Fair value HK$0.1349 · Fairly valued 
Mixed vs. peers (4/9) 
Quality 33/100 
Falling price (downtrend) 
Weak Growth (revenue 3y −38.8 %/yr in CNY) 
Negative free cash flow 
Narrow moat 6/100 · thin data
Thin data 
Estimate
Watch Rainmed Medical Ltd for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

HK$5.28 HK$0.1300 Fair Value HK$0.1349 Jul 2022 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 10, 2026.

How to read this chart

52‑month range HK$0.1300 – HK$5.28 · fair‑value band HK$0.1011 – HK$0.1686 · the HK$0.1410 price screens above the HK$0.1349 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 10, 2026.

Follow Rainmed Medical in your weekly email

Every Wednesday you see whether Rainmed Medical is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Rainmed Medical Limited operates as a vascular interventional surgical robotics company in China and internationally.

Show moreShow less

It engages in the research and development, manufacturing, and commercialization of medical instruments related to coronary angiography-derived fractional flow reserve (caFFR) systems and coronary angiography-derived index of microvascular resistance (caIMR) systems.

The company also offers FlashAngio caFFR System, a coronary angiography-derived fractional flow reserve measurement system; FlashAngio caIMR System, which provides auxiliary diagnosis of coronary artery diseases; and disposable blood pressure transducer, which is used in conjunction with specialized equipment.

In addition, it provides reagents and others installation and training services. Rainmed Medical Limited was founded in 2014 and is headquartered in Suzhou, China.

Stock analysis

Rainmed Medical Ltd (2297) currently trades at HK$0.1410, while our estimate is HK$0.1349, so the stock looks roughly fairly valued today (gap 4.5%).

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: HK$0.1011 (bear) to HK$0.1686 (bull), the price of HK$0.1410 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 33/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.

Rainmed Medical Ltd reported revenue of 19.2M CNY in FY2025 versus 81.2M CNY in FY2021, a compound −30.3%/yr. Reported net income was −77.1M CNY in FY2025.

Key figures

Market cap HK$198M (≈ $25.2M) Micro · P/S ratio 10.4 · Return on equity −18.8% · Return on assets (EBIT) −21.1% (5-year average) · Operating margin −165% · Revenue (TTM) 23.4M CNY · Revenue growth (YoY) +41.0% · Free cash flow −79.7M CNY.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 6 out of 100 (low confidence).

What moves the price

The share trades about 53% below its 52-week high and at its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 7% fair-value upside, at −4%, 2297 screens richer than that median.

Fair Value

Bear HK$0.1011 Fair Value HK$0.1349 Bull HK$0.1686
Price HK$0.1410 · Downside -4.3%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 33/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 1
How much profit the company makes from its sales and capital
Quality Growth 25
Are margins and returns getting better?
Cashflow 11
Do the profits arrive as real cash?
Financial strength 51
Debt, balance sheet and risk of trouble
Investment 72
Does it invest with discipline instead of growing at any price?
Low Volatility 45
How calm the share price moves, does not count
Price momentum 5
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 0
Distance to the 52-week high, does not count
New shares 64
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 38/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
−51.8%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−38.8%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+25.8%
Start year 2020 (pandemic)
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−530.7% (2020) → −413.1% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

Watch 2297, get fair value alerts →

Compare Rainmed Medical Ltd with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 401 stocks

Beats the industry median on 4/8 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 33 · Bottom 25%
Fair Value upside −4.3% · Above median
Profitability
Return on assets −14.1% · Below median
Operating margin (12 months) −165.4% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) 41.0% · Top 25%
Balance sheet
Debt / equity 0.01× · Below median

Valuation Multiplesvs Medical Devices median · lower = cheaper

P/B 0.47× · Cheapest 25%
P/S (12 months) 7.17× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)28 · sector 17
FUTURE (revenue growth)100 · sector 41
PAST (return on equity)0 · sector 0
HEALTH (low debt)99 · sector 97
DIVIDEND (yield)0 · sector 34

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Devices stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Stryker Corporation SYK $309.64 $343.63 +11% vs 2297
Boston Scientific Corporation BSX $44.34 $48.77 +10% vs 2297
Shenzhen Mindray Bio-Medical Electronics Co 300760 ¥179.40 ¥197.34 +10% vs 2297
DexCom, Inc DXCM $83.33 $91.66 +10% vs 2297
STERIS plc STE $264.32 $281.90 +7% vs 2297
GE HealthCare Technologies Inc GEHC $83.02 $69.92 −16% vs 2297
Edwards Lifesciences Corporation EW $107.15 $81.94 −24% vs 2297
Medtronic plc MDT $102.86 $74.90 −27% vs 2297
Abbott Laboratories, ABT $108.52 $75.28 −31% vs 2297
Koninklijke Philips N.V PHIA €27.43 €15.23 −44% vs 2297

Explore undervalued stocks

More undervalued Healthcare stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Rainmed Medical Ltd: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Rainmed Medical Ltd Fair Value". https://www.fairvalue-calculator.com/stock/2297

Frequently asked questions

Is Rainmed Medical Ltd (2297) overvalued or undervalued?
As of Nov 10, 2026, our estimate of fair value is HK$0.1349 versus a price of HK$0.1410, about 4% lower (fairly valued).
What is the fair value of 2297?
Our estimate for Rainmed Medical Ltd is HK$0.1349 (as of Nov 10, 2026), built from audited fundamentals. The current price: HK$0.1410.
What is the quality score of 2297?
Rainmed Medical Ltd has a Quality Score of 33/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Rainmed Medical Ltd (2297)?
Our calculated price target is the estimate of HK$0.1349 (as of Nov 10, 2026). Cautious scenario HK$0.1011, optimistic scenario HK$0.1686. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the Rainmed Medical Ltd stock forecast for 2026?
Our estimate puts fair value at HK$0.1349, about 4% lower versus a price of HK$0.1410 (fairly valued). Cautious scenario HK$0.1011, optimistic scenario HK$0.1686. The calculation is refreshed regularly with new filings.
What is the revenue of Rainmed Medical Ltd (2297)?
Rainmed Medical Ltd reported trailing-twelve-month revenue of about 23.4M CNY (latest available figure, as of Nov 10, 2026).
What is the intrinsic value of Rainmed Medical Ltd (2297)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Rainmed Medical Ltd it is HK$0.1349 per share (as of Nov 10, 2026), against a price of HK$0.1410.
Is Rainmed Medical Ltd stock overvalued or undervalued in 2026?
As of Nov 10, 2026, 2297 trades above its calculated fair value: price HK$0.1410, fair value HK$0.1349, a gap of about −4% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 2297?
No. The price is what the market pays today (HK$0.1410); the fair value is what the company's own numbers justify (HK$0.1349). For Rainmed Medical Ltd the two are HK$0.0061 per share apart. That gap is exactly why we show both numbers side by side.
How much is Rainmed Medical Ltd worth?
The market values Rainmed Medical Ltd at about HK$198M (market capitalisation, as of Nov 10, 2026). Per share that is HK$0.1410; our models calculate a fair value of HK$0.1349 per share.
What do the bullish and bearish scenarios say about 2297?
Our models span a range for Rainmed Medical Ltd: cautious scenario HK$0.1011, base HK$0.1349, optimistic HK$0.1686 per share (as of Nov 10, 2026, price HK$0.1410). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Rainmed Medical Ltd (2297)?
Balance-sheet figures for Rainmed Medical Ltd (as of Nov 10, 2026): return on equity −18.8%, debt of 0.01 per unit of equity. They feed the Quality Score of 33/100, which measures business quality independently of the share price.
How far is 2297 from its 52-week high?
Rainmed Medical Ltd trades at HK$0.1410, about 53% below its 52-week high of HK$0.3000 and at the low of HK$0.1410 (as of Nov 13, 2026). Distance from the high says nothing about value: that is what the fair value of HK$0.1349 is for.
Which stocks are comparable to Rainmed Medical Ltd?
From the same area (Healthcare) we also value Abbott Laboratories,, Medtronic plc, Stryker Corporation, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Rainmed Medical Ltd stock attractive at the current price?
The data as of Nov 10, 2026: price HK$0.1410, calculated fair value HK$0.1349 (−4%), Quality Score 33/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5% above its aggregate fair value. Rainmed Medical Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Rainmed Medical Ltd (2297)?
The closing price on Nov 13, 2026 was HK$0.1410. Our estimate is HK$0.1349, about 4% lower (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Rainmed Medical Ltd right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of Rainmed Medical Ltd

How large is the market capitalisation of Rainmed Medical Ltd (2297)?
The market capitalisation of Rainmed Medical Ltd is HK$198M (≈ $25.2M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Rainmed Medical Ltd (2297)?
The price-to-sales ratio of Rainmed Medical Ltd is 10.4 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the return on equity of Rainmed Medical Ltd (2297)?
The return on equity (ROE) of Rainmed Medical Ltd is −18.8% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Rainmed Medical Ltd (2297)?
On an EBIT basis the return on assets of Rainmed Medical Ltd is −21.1% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Rainmed Medical Ltd (2297)?
The operating margin of Rainmed Medical Ltd is −165% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Rainmed Medical Ltd (2297)?
Revenue at Rainmed Medical Ltd is growing 41.0% versus a year earlier (3y avg −38.8%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Rainmed Medical Ltd (2297) generate?
The free cash flow of Rainmed Medical Ltd is −79.7M CNY (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Rainmed Medical Ltd (2297) carry?
The net debt of Rainmed Medical Ltd is 10.4M CNY (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Rainmed Medical Ltd in the live analysis

One click puts Rainmed Medical Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.